International Research in Cambodia: Tropical Medicine and Vector Research

$301,091ZIAFY2017AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Paper 38889712 Paper 38751433 Paper 37221466 Paper 36654682 Paper 36649803 Paper 35895370 Paper 35238677 Paper 34718636 Paper 32534628 Paper 32394887 Paper 30669682 Paper 30572920 Paper 30326952 Paper 29720620 Paper 29398391 Paper 28494763 Paper 28289193 Paper 27825353 Paper 27818095 Paper 27798646 Paper 27660233 Paper 27577697 Paper 27348299 Paper 27337450 Paper 26774243 Paper 26742574 Paper 26701602 Paper 26485448 Paper 26390866 Paper 26283745 Paper 26237549 Paper 25928499 Paper 25851174 Paper 25712365 Paper 25599401 Paper 25502314 Paper 25075834 Paper 25049249 Paper 24948693 Paper 24923250 Paper 24867977 Paper 24867976 Paper 24849722 Paper 24352242 Paper 24338354 Paper 24225303 Paper 24035558 Paper 23939897 Paper 23733143 Paper 23624527 Paper 23612201 Paper 23562882 Paper 23347631 Paper 22855752 Paper 22722859 Paper 22445352 Paper 22321373 Paper 21992120 Paper 21673999 Paper 21532754 Paper 20101240

Abstract

(1)We have preliminary evidence that triple artemisinin combination therapy (TACT), comprising dihydroartemisinin-piperaquine+mefloquine (DHA-PPQ+MQ)is safe, tolerable and efficacious in treating DHA-PPQ-resistant Plasmodium falciparum malaria in Cambodia. (2)We have preliminary evidence to suggest that artemisinin resistance has entered a second phase in Cambodia, where a specific lineage of multidrug resistant parasites have swept through the P. falciparum population and is starting to spread to other areas. (3)We have shown a great diversity of malaria vectors in Cambodia as well as potential for cow-baited tents as a vector control tool. (4)We have started the first genome analysis of individual malaria vectors outside of Africa.

View original record on NIH RePORTER →